Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (5318)	1/3/2002 8:48:46 PM
From: scaram(o)uche	Respond to of 52153

Nope, but the hunker down, fundamentally undervalued stuff is doing great. And the low MC:book potential flyers are not yet attracting "January Effect"-like interest. It's once again stock-picker's heaven. Today's Missouri-Columbia/Immerge (BTRN/Novartis) news may well be a big step toward an enormous market. I am not one of those who believe that it's the only major step. But..... it's a major advance. It shouldn't be forgotten that BTRN (Immerge) already had inbred miniswine (at least eight backcrosses, and I believe more than 10). I presume, but do not know, that BTRN's collaborator, Infigen, will apply the Missouri-Columbia results to the inbred minis. A couple of weeks ago, I was ticked to see the shelf offering on the shelf. Not now. It'll be interesting to hear what MEDI has to say about 507 at H&Q.